Table 6 Top 10 KEGG pathway enrichment results comparison between (A) single data set analysis and (B) joint analysis in Huntington’s disease
Term | Count | Enrichment Pvalue | Bonferroni corrected P |
|---|---|---|---|
(A) Single | |||
hsa03050:Proteasome | 12 | 5.14E-07 | 1.21E-04 |
hsa05010:Alzheimer’s disease | 20 | 1.95E-05 | 0.004579209 |
hsa05012:Parkinson’s disease | 18 | 2.58E-05 | 0.006034046 |
hsa05016:Huntington’s disease | 19 | 3.66E-04 | 0.08242395 |
hsa05033:Nicotine addiction | 7 | 0.003777846 | 0.589128604 |
hsa00190:Oxidative phosphorylation | 13 | 0.004721495 | 0.671158323 |
hsa04932:Non-alcoholic fatty liver disease (NAFLD) | 14 | 0.00497103 | 0.689975889 |
hsa05169:Epstein-Barr virus infection | 15 | 0.013743654 | 0.9613094 |
hsa04723:Retrograde endocannabinoid signaling | 10 | 0.01471692 | 0.969321024 |
hsa04728:Dopaminergic synapse | 11 | 0.02422846 | 0.996860832 |
(B) Joint | |||
hsa05012:Parkinson’s disease | 29 | 3.18E-13 | 7.59E-11 |
hsa00190:Oxidative phosphorylation | 27 | 2.90E-12 | 6.92E-10 |
hsa05016:Huntington’s disease | 32 | 4.34E-12 | 1.04E-09 |
hsa05010:Alzheimer’s disease | 29 | 2.33E-11 | 5.57E-09 |
hsa04932:Non-alcoholic fatty liver disease (NAFLD) | 22 | 2.14E-07 | 5.12E-05 |
hsa03050:Proteasome | 10 | 3.21E-05 | 0.007653523 |
hsa01100:Metabolic pathways | 73 | 5.47E-05 | 0.012999463 |
hsa05169:Epstein-Barr virus infection | 20 | 1.02E-04 | 0.024158392 |
hsa04721:Synaptic vesicle cycle | 10 | 5.70E-04 | 0.127417187 |
hsa01200:Carbon metabolism | 13 | 0.001156092 | 0.241540496 |